Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company, announces that Health Canada has approved Probuphine (buprenorphine subdermal implant) for the management of opioid dependence […]
Mylan N.V. and Revance Therapeutics, Inc. announce a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA). BOTOX […]
MilliporeSigma introduces the Viresolve Barrier capsule filters to reduce the risk of bioreactor contamination. The filters are designed to remove viruses, mycoplasma and bacteria from cell culture media.
The GeneTitan Multi-Channel Instrument from Thermo Fisher Scientific offers streamlining array processing for discovery, exploration, and screening. The GeneTitan Instrument for expression applications and the […]
Orfadin, an oral suspension which is meant to treat hereditary tyrosinemia type 1 (HT-1), has been approved by Health Canada.
A recent forecast expects the global insomnia therapeutics market to reach US$3.45 billion by 2025.